In rare cases, participants reported constipation or transient dizziness
Mounjaro : dual-hormone action with greater weight loss (20%+)
Meanwhile, a post-hoc analysis of the STEP 1 and STEP 4 trials showed that semaglutide 2.4 mg was associated with an approximately 60% reduction of the 10-years risk of T2D according to the Cardiometabolic Disease Staging (CMDS) calculator, regardless of patients baseline glycemic status 74
The medication is commonly used alongside metformin, with the combination often providing complementary mechanisms of action for improved glycemic control
Mounjaro (tirzepatide) mimics two hormones, GLP-1 and GIP
As your body adapts to weight loss, it may become more energy-efficient, which can naturally lead to plateaus